Welcome to our dedicated page for Caris Life Sciences SEC filings (Ticker: CAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Caris Life Sciences, Inc. (NASDAQ: CAI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Texas corporation with Commission File Number 001-42706, Caris uses current reports on Form 8-K and other SEC filings to communicate information about financial results, corporate governance changes and other material events.
Recent 8-K filings from Caris Life Sciences have furnished press releases announcing quarterly financial results, including revenue from molecular profiling services and pharma research and developmental services, as well as clinical therapy selection case volumes. Another 8-K describes an amendment and restatement of the company’s bylaws, including a provision specifying the minimum beneficial ownership threshold required for shareholders to institute or maintain a derivative proceeding under Texas law.
On this page, users can review CAI filings such as Form 8-K, and, as they become available, annual reports on Form 10-K, quarterly reports on Form 10-Q, and other documents that detail Caris’ business, risk factors, financial condition and governance matters. These filings complement the company’s press releases by providing formal, structured disclosures for investors and analysts.
Stock Titan enhances access to these documents with tools designed to help readers navigate and interpret complex SEC materials. Users can monitor new CAI filings as they are posted to the EDGAR system and use AI-powered summaries to understand key points in lengthy reports, including discussions of molecular profiling operations, precision oncology initiatives, and corporate policies referenced in Caris Life Sciences’ regulatory disclosures.
Caris Life Sciences director Peter M. Castleman reported an option exercise and updated share holdings. On January 9, 2026, he exercised a stock option to acquire 2,500 shares of common stock at an exercise price of $18.6 per share, increasing his directly held common stock to 18,629 shares. The stock option position reported in this filing is now shown as 0 derivative securities remaining.
Castleman also reports indirect ownership of 100,000 common shares through a family trust and 10,270,906 common shares held by CLS-PF-SPE, LLC, where he has voting and investment power through CLS-PF-SPE Manager, LLC, while disclaiming beneficial ownership except to the extent of his pecuniary interest. The option was already fully vested and had been previously reported on his Form 3.
Caris Life Sciences, Inc. furnished an 8-K to report that it issued a press release with certain preliminary unaudited financial results for the quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference for this results disclosure. The company also states that materials used for its presentation at the 2026 J.P. Morgan Healthcare Conference will be posted to its investor relations website. The information in this report, including the exhibit, is being furnished rather than filed, which limits its use in other securities law contexts.
Caris Life Sciences, Inc.12/11/2025. The officer exercised stock options to acquire 24,750 and 37,500 shares of common stock at an exercise price of $2.44 per share.
On the same date, the officer sold 60,850 shares at a weighted average price of $26.5644 and 1,400 shares at a weighted average price of $27.1554, in multiple transactions within stated price ranges. These option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. Following the transactions, the officer directly owns 99,571 shares of Caris Life Sciences common stock, and the reported stock options have been fully exercised.
Caris Life Sciences, Inc. reported that one of its directors and executive officers, who serves as Vice Chairman and Executive Vice President, made two stock gifts of the company’s common stock. On 12/10/2025 and 12/11/2025, the insider transferred 650 shares on each date as gifts at a reported price of $0 per share, reflecting that these were non-cash transfers.
After these transactions, the insider beneficially owns 161,128 shares of Caris common stock directly. In addition, 500,000 shares are reported as indirectly owned through trusts, with the insider stating that beneficial ownership of those shares is disclaimed except to the extent of any pecuniary interest. No derivative securities were reported.
Caris Life Sciences (CAI) reported an insider purchase on a Form 4. J. Russel Denton, Senior Vice President, General Counsel, and Secretary, bought 4,184 shares of common stock on 11/07/2025 at a weighted average price of $24.09, with trades executed between $23.99 and $24.15.
After this transaction, he beneficially owns 9,184 shares indirectly by trust and 123,591 shares directly. The price range note indicates multiple trade executions aggregated into the reported average.
Caris Life Sciences (CAI) filed a Form 4 reporting an open‑market purchase by its President. On 11/07/2025, the officer bought 400 shares of common stock at $23.85 (transaction code P). Following the trade, the reporting person beneficially owns 460,777 shares, held directly.
Caris Life Sciences (CAI) filed its Q3 2025 10‑Q. Revenue rose to $216.8 million from $101.6 million a year ago, driven mainly by molecular profiling services ($207.6 million). Operating results improved to income of $32.6 million from a loss, with net income of $24.3 million versus a prior-year net loss.
For the nine months, revenue reached $519.1 million (from $282.3 million), while the company recorded a net loss of $150.0 million, reflecting non-operating items including fair value changes and financing effects. Cash, cash equivalents, and restricted cash were $757.0 million at period end, supporting total assets of $984.6 million.
Following its June IPO at $21.00 per share, preferred shares and 2025 convertible notes converted into common stock, and certain warrants were exercised. Shareholders’ equity improved to $478.4 million from a prior deficit, with 282.1 million common shares outstanding as of September 30, 2025.
Caris Life Sciences, Inc. furnished an 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025.
The release, dated November 5, 2025, is provided as Exhibit 99.1 and is incorporated by reference solely for Item 2.02. The company states this information is furnished, not filed, under the Exchange Act.
Caris Life Sciences (CAI) amended and restated its bylaws. Effective upon Board approval on October 30, 2025, a shareholder—defined under the Texas Business Organizations Code to include a group acting together—must beneficially own at least 3% of the company’s outstanding common stock at the time a case is filed to institute or maintain a derivative proceeding.
The change is described under Item 5.03 and incorporated into Item 3.03 as a material modification to rights of security holders. The full text of the amended and restated bylaws is provided as Exhibit 3.1.
George Poste, a director of Caris Life Sciences (CAI), reported option exercise and share dispositions on 08/11/2025 resulting in changes to his beneficial ownership.
The filing shows a 125,000-share option exercise at $2.44, recorded as an acquisition. The report also lists two dispositions of common stock: 48,022 shares and 91,495 shares, each at $29.75. Table entries show sequential direct beneficial ownership figures of 359,754, 311,732 and 220,237 following the reported transactions, and an indirect holding of 307,594 shares through a family trust. The filing notes the underlying stock option is fully vested and exercisable, and the form was signed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Caris Life Sciences (CAI)?
What is the market cap of Caris Life Sciences (CAI)?
